These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35803528)

  • 21. Loss of Hepatic Surf4 Depletes Lipid Droplets in the Adrenal Cortex but Does Not Impair Adrenal Hormone Production.
    Chang X; Zhao Y; Qin S; Wang H; Wang B; Zhai L; Liu B; Gu HM; Zhang DW
    Front Cardiovasc Med; 2021; 8():764024. PubMed ID: 34859075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.
    Fu T; Mukhopadhyay D; Davidson NO; Borensztajn J
    J Biol Chem; 2004 Jul; 279(27):28662-9. PubMed ID: 15123680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defective VLDL metabolism and severe atherosclerosis in mice expressing human apolipoprotein E isoforms but lacking the LDL receptor.
    Knouff C; Briand O; Lestavel S; Clavey V; Altenburg M; Maeda N
    Biochim Biophys Acta; 2004 Aug; 1684(1-3):8-17. PubMed ID: 15450205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.
    Medh JD; Fry GL; Bowen SL; Ruben S; Wong H; Chappell DA
    J Lipid Res; 2000 Nov; 41(11):1858-71. PubMed ID: 11060356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets.
    Himber J; Missano B; Rudling M; Hennes U; Kempen HJ
    J Lipid Res; 1995 Jul; 36(7):1567-85. PubMed ID: 7595080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.
    Han S; Liang CP; Westerterp M; Senokuchi T; Welch CL; Wang Q; Matsumoto M; Accili D; Tall AR
    J Clin Invest; 2009 Apr; 119(4):1029-41. PubMed ID: 19273907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR(-/-) and ApoE(-/-) mice.
    Ryu SK; King TJ; Fujioka K; Pattison J; Pashkow FJ; Tsimikas S
    Atherosclerosis; 2012 May; 222(1):99-105. PubMed ID: 22406426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
    Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
    Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE.
    van Dijk KW; van Vlijmen BJ; van't Hof HB; van der Zee A; Santamarina-Fojo S; van Berkel TJ; Havekes LM; Hofker MH
    J Lipid Res; 1999 Feb; 40(2):336-44. PubMed ID: 9925664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of dietary lipids on hepatic mRNA levels of proteins regulating plasma lipoproteins in baboons with high and low levels of large high density lipoproteins.
    Kushwaha RS; McMahan CA; Mott GE; Carey KD; Reardon CA; Getz GS; McGill HC
    J Lipid Res; 1991 Dec; 32(12):1929-40. PubMed ID: 1687745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y; Liu XQ; Rall SC; Mahley RW
    J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of microRNA-378a-3p biogenesis promotes hepatic secretion of VLDL and hyperlipidemia by modulating ApoB100-Sortilin1 axis.
    Zhang T; Shi H; Liu N; Tian J; Zhao X; Steer CJ; Han Q; Song G
    Theranostics; 2020; 10(9):3952-3966. PubMed ID: 32226531
    [No Abstract]   [Full Text] [Related]  

  • 34. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
    Post SM; de Roos B; Vermeulen M; Afman L; Jong MC; Dahlmans VE; Havekes LM; Stellaard F; Katan MB; Princen HM
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice.
    Karavia EA; Papachristou DJ; Kotsikogianni I; Giopanou I; Kypreos KE
    FEBS J; 2011 Sep; 278(17):3119-29. PubMed ID: 21740524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr-/- Mice.
    Park JG; Xu X; Cho S; Lee AH
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1772-81. PubMed ID: 27417587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of lipid metabolism with the overexpression of NPC1L1 in mouse liver.
    Kurano M; Hara M; Tsuneyama K; Okamoto K; Iso-O N; Matsushima T; Koike K; Tsukamoto K
    J Lipid Res; 2012 Nov; 53(11):2275-85. PubMed ID: 22891292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High fat / high cholesterol diet does not provoke atherosclerosis in the ω3-and ω6-polyunsaturated fatty acid synthesis-inactivated Δ6-fatty acid desaturase-deficient mouse.
    Stoffel W; Binczek E; Schmidt-Soltau I; Brodesser S; Wegner I
    Mol Metab; 2021 Dec; 54():101335. PubMed ID: 34530175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice.
    Draijer R; Volger OL; Dahlmans VE; de Wit EC; Havekes LM; Princen HM
    Biochem Pharmacol; 2002 May; 63(9):1755-61. PubMed ID: 12007578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.